1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-17 am EDT
11002.00 GBX   +0.31%
09:25aMARKETSCREENER’S WORLD PRESS REVIEW : August 17, 2022
MS
08:43aAstraZeneca and Merck - FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration
AQ
03:51aSanofi trial failure ends development of breast cancer treatment amcenestrant
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : invests in Imperial's self-amplifying RNA technology with eye on future drugs

09/23/2021 | 02:21am EDT
FILE PHOTO: Exterior photos of the North America headquarters of AstraZeneca

LONDON (Reuters) - AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London's experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.

Under the deal, VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.

AstraZeneca already produces an adenoviral vector COVID-19 vaccine, and emphasised the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programmes beyond the coronavirus pandemic.

"This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox," said AstraZeneca research chief Mene Pangalos.

The technology works in a similar way to the messenger RNA (mRNA) vaccines made by Pfizer/BioNTech and Moderna.

However, a self-amplifying RNA vaccine not only encodes the instructions for the host cell to make a coronavirus protein, but makes lots of copies of the RNA containing those instructions, meaning doses can be smaller and cheaper.

"It's a bit like having a manufacturing facility, and instead of having one copy of the recipe, you have multiple copies that you can hand round to multiple production lines within the cell to produce more protein," Imperial's Shattock told Reuters. "So that's why it has that opportunity to use lower doses."

Imperial's COVID-19 vaccine is being retooled to produce a more consistent immune response with an eye on future coronavirus variants.

AstraZeneca, under the deal, has the option to collaborate on 26 drug targets for use against other therapeutic areas like cancers and rare genetic diseases.

"We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest," Pangalos said.

U.S. companies Gritstone bio and Arcturus also are developing saRNA COVID-19 vaccines.

Shattock said safety data had been encouraging from initial trials of its COVID-19 vaccine, released in July ahead of peer review, and that Phase I results of its refined vaccine would be ready early next year.

"The reason we were slower was because we were coming from an academic setting," he said. "If we had this relationship (with AstraZeneca) at the beginning of 2020, we might have been faster."

(Reporting by Alistair Smout; Additional reporting by Christine Soares; Editing by Bill Berkrot)

By Alistair Smout


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.31% 11002 Delayed Quote.26.39%
GRITSTONE BIO, INC. -7.79% 4.38 Delayed Quote.-63.06%
MODERNA, INC. -5.93% 158 Delayed Quote.-33.87%
All news about ASTRAZENECA PLC
09:25aMARKETSCREENER’S WORLD PRESS REVIEW : August 17, 2022
MS
08:43aAstraZeneca and Merck - FDA Accepts Submission of Supplemental New Drug Application for..
AQ
03:51aSanofi trial failure ends development of breast cancer treatment amcenestrant
RE
01:47aSanofi trial failure halts work on breast cancer treatment amcenestrant
RE
08/16Australia biotech giant CSL reports profit dip, flags cost spiral
RE
08/16Lynparza in combination with abiraterone granted Priority Review in the US for patient..
AQ
08/16AstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK
MT
08/16AstraZeneca Granted FDA Priority Review for Prostate Cancer Combination Therapy
MT
08/16LYNPARZA« (olaparib) in combination with abiraterone granted Priority Review in the US ..
BU
08/16ASTRAZENECA : Lynparza in combination with abiraterone granted Priority Review in the US f..
PU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 238 M - -
Net income 2022 4 399 M - -
Net Debt 2022 24 039 M - -
P/E ratio 2022 47,3x
Yield 2022 2,22%
Capitalization 205 B 205 B -
EV / Sales 2022 5,19x
EV / Sales 2023 4,82x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 132,52 $
Average target price 144,13 $
Spread / Average Target 8,76%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC26.39%205 636
JOHNSON & JOHNSON-2.05%440 572
ELI LILLY AND COMPANY12.34%294 849
PFIZER, INC.-15.56%279 832
ROCHE HOLDING AG-16.74%273 886
ABBVIE INC.5.28%252 042